List view / Grid view
11 May 2015 | By Victoria White
PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers...
11 May 2015 | By Victoria White
Isarna Therapeutics presented preclinical data for its lead candidate ISTH0036 in one podium presentation and two poster publications at ARVO 2015...
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
8 May 2015 | By Victoria White
Boronicaine is a new compound that offers longer lasting painkilling effects and shows promise as an alternative to current anaesthetics...
8 May 2015 | By Victoria White
MorphoSys has acquired Lanthio Pharma. The acquisition adds novel candidates including a pre-IND candidate for fibrotic diseases to MorphoSys's portfolio...
8 May 2015 | By Victoria White
Researchers have determined the molecular structure of amyloid beta-42, one of the proteins in the brain plaques that are a hallmark of Alzheimer’s disease...
8 May 2015 | By Victoria White
Researchers at the University of Copenhagen have discovered how to map more than one protein at a time, when proteins repair damaged DNA.
7 May 2015 | By Victoria White
University of British Columbia researchers have reported that a new anticonvulsant epilepsy drug holds promise as a treatment for Alzheimer’s disease...
7 May 2015 | By Victoria White
Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells...
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
7 May 2015 | By Victoria White
Pfizer has made two strategic appointments in the leadership of their BioTherapeutics Research and Development and Rinat units...
6 May 2015 | By Victoria White
Dicerna Pharmaceuticals has presented positive preclinical data on its proprietary DsiRNA-EX Conjugate-mediated delivery technology at TIDES 2015...
6 May 2015 | By Victoria White
Scientists at The Institute of Cancer Research have found that ROCK inhibitors dramatically reduced the ability of melanoma cells to move through tissue...
6 May 2015 | By Victoria White
Gilead Sciences has acquired EpiTherapeutics, a scientific leader in the field of epigenetics with a library of first-in-class inhibitors, for $65 million.
6 May 2015 | By Victoria White
The final report on toxicology testing of HuMab 5B1 shows that it had no significant adverse findings even at the highest dosage levels tested...
